This statistic depicts the percentage of medtech and biopharma firms that are likely to move or locate intellectual property back to the U.S. after the U.S. tax reform, according to a survey conducted during summer 2018. According to the survey, 10 percent of companies are significantly unlikely to move their intellectual property back to the U.S. at that time.
Percentage of biopharma and medtech companies that are more likely to develop intellectual property (IP) in the U.S. due to tax reforms as of 2018
Original question: "Has U.S. tax reform increased or decreased the likelihood your company will move intellectual property (IP) back to the United States or locate a new IP in the United States?"
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Deloitte. (October 26, 2018). Percentage of biopharma and medtech companies that are more likely to develop intellectual property (IP) in the U.S. due to tax reforms as of 2018 [Graph]. In Statista. Retrieved October 19, 2024, from https://www.statista.com/statistics/954458/intellectual-property-development-in-us-by-life-sciences-companies/
Deloitte. "Percentage of biopharma and medtech companies that are more likely to develop intellectual property (IP) in the U.S. due to tax reforms as of 2018." Chart. October 26, 2018. Statista. Accessed October 19, 2024. https://www.statista.com/statistics/954458/intellectual-property-development-in-us-by-life-sciences-companies/
Deloitte. (2018). Percentage of biopharma and medtech companies that are more likely to develop intellectual property (IP) in the U.S. due to tax reforms as of 2018. Statista. Statista Inc.. Accessed: October 19, 2024. https://www.statista.com/statistics/954458/intellectual-property-development-in-us-by-life-sciences-companies/
Deloitte. "Percentage of Biopharma and Medtech Companies That Are More Likely to Develop Intellectual Property (Ip) in The U.S. Due to Tax Reforms as of 2018." Statista, Statista Inc., 26 Oct 2018, https://www.statista.com/statistics/954458/intellectual-property-development-in-us-by-life-sciences-companies/
Deloitte, Percentage of biopharma and medtech companies that are more likely to develop intellectual property (IP) in the U.S. due to tax reforms as of 2018 Statista, https://www.statista.com/statistics/954458/intellectual-property-development-in-us-by-life-sciences-companies/ (last visited October 19, 2024)
Percentage of biopharma and medtech companies that are more likely to develop intellectual property (IP) in the U.S. due to tax reforms as of 2018 [Graph], Deloitte, October 26, 2018. [Online]. Available: https://www.statista.com/statistics/954458/intellectual-property-development-in-us-by-life-sciences-companies/